What radiation dose and fractionation is recommended for pleomorphic adenoma of the salivary glands?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Radiation Dose for Pleomorphic Adenoma

Pleomorphic adenoma is a benign tumor that does not require radiotherapy after complete surgical excision; however, when radiotherapy is indicated for incompletely resected or recurrent disease, standard fractionation with 65 Gy to the tumor bed is recommended. 1

Primary Treatment Approach

  • Surgery alone is the definitive treatment for pleomorphic adenoma, with complete excision beyond the pseudocapsule being essential to prevent recurrence. 2, 3

  • No adjuvant radiotherapy is indicated after macroscopically and microscopically complete resection, even though this is a benign tumor with potential for recurrence. 1

  • For major salivary glands (particularly parotid), superficial or total parotidectomy with facial nerve preservation achieves local control rates of 95% or higher. 3

Indications for Radiotherapy

Radiotherapy should be reserved for specific clinical scenarios where surgery alone is insufficient:

  • Incomplete surgical margins (tumor at excision margins on histology) 1

  • Unresectable tumors where complete excision would cause significant functional or cosmetic deficit 3

  • Multifocal recurrences after prior surgical resection 3

Radiation Dose and Fractionation

When radiotherapy is required, the recommended approach is:

  • Standard fractionation with photons (±electrons) 1

  • 65 Gy to the tumor bed 1

  • Dose to cervical lymph nodes should be adjusted according to nodal status (though nodal involvement is not typical for benign pleomorphic adenoma) 1

Expected Outcomes with Radiotherapy

  • Microscopic residual disease: Local control rates of approximately 80-85% 3

  • Gross residual disease: Local control rates of approximately 40-60% 3

  • These outcomes are substantially lower than the >95% control achieved with complete surgical excision, reinforcing that surgery remains the primary treatment modality 3

Critical Caveats

Avoid routine radiotherapy for completely excised pleomorphic adenoma because:

  • Late recurrences (15-20 years post-treatment) may be more likely to undergo malignant transformation when radiation has been used 4

  • One study documented a cumulative 20-year recurrence rate of 8% after local excision plus radiotherapy, with late recurrences being predominantly malignant tumors 4

  • At least one case was likely radiation-induced malignancy, though radiation may have increased the incidence of spontaneous malignant transformation in others 4

The key surgical principle is achieving intact capsule excision with adequate margins, which when confirmed histologically, eliminates the need for radiotherapy and long-term follow-up. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Imaging and Surgical Management of Benign Major Salivary Gland Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Salivary gland pleomorphic adenoma.

American journal of clinical oncology, 2008

Research

Long-term results of local excision and radiotherapy in pleomorphic adenoma of the parotid.

International journal of radiation oncology, biology, physics, 1985

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.